Pairing Cancer Biomarkers to Biomedicine

Pairing Cancer Biomarkers to Biomedicine

On May 23, 2017, the US Food and Drug Administration (FDA) approved pembrolizumab for the treatment of any solid tumors with certain specific genetic features or biomarkers, namely microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This was the first time that the FDA approved a cancer treatment based on a common biomarker, rather than the organ site or histology. Pemb...

cancer biomarkers

Use of Apoptotic Biomarkers to Predict Response to Radiotherapy in Breast Cancer Patients

Introduction: To enhance radiation therapy efficiency it is crucial to implement an individual-based treatment. The aim of present study was to identify the mechanism of intrinsic apoptosis pathway on radiosensitivity and normal tissue complications caused by the radiotherapy.   Materials and Methods: radiation-induced apoptosis in periphera...

MicroRNAs as biomarkers associated with bladder cancer

Bladder cancer is the fifth most common cancer with significant morbidity and mortality. Recently, numerous studies demonstrated that microRNAs are emerging as diagnostic biomarkers for bladder cancer. Specific miRNA profiles have been identified for several samples from patients with bladder cancer. MicroRNAs are noncoding RNA molecules of approximately 23 nucleotides that play important roles...

Role of Molecular Biomarkers in Colorectal Cancer

Colorectal cancer (CRC) is amongst the most widespread cancers and is a most common cause of cancer associated mortality universally. Since previous decades, it has been cleared that CRC develops owing to the buildup of a series of genetic and epigenetic changes in the normal colonic epithelium. Regardless of the current development in surgery and therapies, overall survival of end stage CRC pa...